U.S. market Closed. Opens in 2 hours 7 minutes

BRNS | Barinthus Biotherapeutics plc Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue805.11K44.70M268.00K4.82M6.87M
Cost of Revenue3.11KN/AN/AN/A0
Gross Profit802.00K44.70M268.00K4.82M6.87M
Operating Expenses85.04M47.50M41.49M21.59M32.30M
Selling, General & Admin40.00M6.39M25.12M10.48M2.33M
Research & Development45.05M41.11M16.37M11.11M29.97M
Other Operating Expenses1.08M567.00K332.00K42.00K0
Operating Income-84.24M-4.04M-45.22M-20.05M-25.77M
Other Expenses / Income7.42M567.00K-7.25M2.53M2.98M
Before Tax Income-76.82M850.00K-51.14M-17.84M-22.79M
Income Tax Expenses-3.09M-4.47M-28.00K95.00K-2.02M
Net Income-73.63M5.34M-50.87M-17.71M-20.82M
Interest Expenses28.11K19.00K2.67M3.60M133.30K
Basic Shares Outstanding38.39M37.25M37.19M47.65KN/A
Diluted Shares Outstanding38.39M38.17M37.19M47.65KN/A
EBITDA-71.06M5.19M-40.28M-16.52M-25.42M
EBITDA Margin-8,826.77%11.61%-15,031.34%-342.61%-369.89%
EBIT-76.69M890.00K-48.23M-14.01M-22.70M
EBIT Margin-9,525.44%1.99%-17,994.40%-290.62%-330.24%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙